News & Trends - Pharmaceuticals

Blood pressure drugs associated with double rate of cognitive decline

Health Industry Hub | October 14, 2020 |
[Total: 1    Average: 4/5]

Pharma News: A blood pressure reading that is greater than 140 mmHg and left untreated will significantly worsen cognitive decline in older persons. However, systolic blood pressure that is lower than 120 mmHg and is treated with antihypertensive medications may also increase cognitive decline, according to new research from the Centre for Healthy Brain Ageing (CHeBA) at UNSW Sydney.

Late-life hypertension has been associated with better cognitive outcomes in several studies. Many questions remain, including the relative benefit or harm of a blood pressure (BP) target and antihypertensive therapy of <120 in very old individuals.

The study, published in The Journal of Gerontology: Medical Sciencesis important given the 2017 changes to blood pressure management guidelines that recommended blood pressure should be maintained below 120/80mmHg.

Dr Matt Lennon, a medical doctor and lead author on the study, said “Medical practitioners are being advised in people older than 70 that systolic blood pressure should be kept below 120 mmHg. Our study indicated that participants using antihypertensives with that blood pressure reading ended up with worsened cognitive decline.

“Over the course of our study they had approximately doubled the rate of cognitive decline compared to the average participant,” said Dr Lennon. 

“We also found that participants with blood pressure greater than 140 mmHg who did not use antihypertensives had similar worsened rates of cognitive decline, approximately double the average participant over the course of the study.

The research compared the cognitive outcomes of 1,015 people from the Sydney Memory and Ageing Study aged 70-90 in three distinct systolic blood pressure groups. It was conducted over a 6-year period.

Dementia is the second leading cause of death in Australia and the single greatest cause of disability in older Australians (aged 65 years and older) and the third leading cause of disability burden overall.  In 2020 there is an estimated 459,000 Australians living with dementia and without a medical breakthrough, the number is expected to increase to over one million people by the middle of the century. 

Co-Director of CHeBA and author on the paper, Professor Perminder Sachdev, said that ongoing treatment at new recommendations of lower systolic blood pressure targets should be considered carefully in older populations. 

“High blood pressure is one of the most prevalent risk factors for dementia, affecting 1 in 4 adults and one billion people worldwide,” said Professor Sachdev.

“Maintain blood pressure at appropriate levels through all stages in life must be part of prevention strategy if we are the mitigate the effects of dementia on our society in the future.”

Dr Lennon said that it is important for patients and their families to know what their ideal blood pressure is for their age and to be aware of damaging cognitive effects of blood pressure that is too high or too low.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Medtronic recognised in the 2020 AFR BOSS most innovative health companies list

Medtronic recognised in the 2020 AFR BOSS most innovative health companies list

Health Industry Hub | October 23, 2020 |

MedTech News: Medtronic Australasia was proud to be recognised as one of Australia and New Zealand’s most innovative companies –ranking […]

More


News & Trends - Biotechnology

Biotech News - Ground-breaking COVID-19 test to not only identify virus but whether patient is infectious

Ground-breaking COVID-19 test to not only identify virus but whether patient is infectious

Health Industry Hub | October 23, 2020 |

Please log in to Health Industry Hub to view this content.
More


News & Trends - Pharmaceuticals

Pharma News - GSK confirms manufacturing site closure at end of 2022

GSK confirms manufacturing site closure at end of 2022

Health Industry Hub | October 22, 2020 |

Pharma News: In July 2020, GSK Australia announced to employees and stakeholders that the Boronia site in VIC would exit […]

More


Leadership & Management

Leadership Management Qualities - Creating the ‘light bulb moment’ on unconscious bias

Creating the ‘light bulb moment’ on unconscious bias

Health Industry Hub | October 21, 2020 |

Please log in to Health Industry Hub to view this content.
More